Insulet (PODD)
(Delayed Data from NSDQ)
$166.19 USD
+2.02 (1.23%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $166.26 +0.07 (0.04%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Price, Consensus and EPS Surprise
PODD 166.19 +2.02(1.23%)
Will PODD be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PODD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PODD
Insulet (PODD) Outperforms Broader Market: What You Need to Know
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
PODD: What are Zacks experts saying now?
Zacks Private Portfolio Services
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Chemed (CHE) Lags Q1 Earnings Estimates, Reaffirms 2024 View
Charles River (CRL) to Report Q1 Earnings: Here's What to Expect
Other News for PODD
Top high growth investment ratio stocks from each sector - GS
ClearBridge Multi Cap Growth Strategy Q1 2024 Portfolio Manager Commentary
ClearBridge Select Strategy Q1 2024 Portfolio Manager Commentary
3 Weight-Loss ETFs to Profit From the Obesity Drug Boom
7 Stable Stocks for 50% Returns by Early 2025